Lurasidone hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1mL, certified reference material, Cerilliant

SKU:
L-030-1ML
  • $196.00

    • Description

    Lurasidone hydrochloride solution 

    1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

    Empirical Formula (Hill Notation):
    C28H36N4O2S · HCl
    CAS Number:
    367514-88-3
    Molecular Weight:
    529.14
    EC Number:
    200-659-6
    MDL number:
    MFCD18917095
    UNSPSC Code:
    41116107
    PubChem Substance ID:
    329817348
    NACRES:
    NA.24

    Properties

    grade

    certified reference material

    Quality Level

    300

    form

    liquid

    feature

    Snap-N-Spike®/Snap-N-Shoot®

    packaging

    ampule of 1 mL

    manufacturer/tradename

    Cerilliant®

    concentration

    1.0 mg/mL in methanol (as free base)

    technique(s)

    gas chromatography (GC): suitable
    liquid chromatography (LC): suitable

    application(s)

    clinical testing

    format

    single component solution

    storage temp.

    −20°C

    SMILES string

    Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)c6nsc7ccccc67

    InChI

    1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1

    InChI key

    NEKCRUIRPWNMLK-SCIYSFAVSA-N

    Gene Information

    human ... DRD2(1813) , HTR2A(3356)

    Description

    General description

    A certified solution standard suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, pharmaceutical research, or urine drug testing. Marketed under the trade name Latuda®, lurasidone is a new atypical antipsychotic developed for the treatment of schizophrenia.

    Application


      • LurasiDonein Bipolar Depression Research: A study explored the pharmacodynamic properties of lurasidone, hypothesizing its efficacy in acute bipolar depression. This research provides a deep dive into the mechanistic actions of lurasidone, enhancing understanding in neuropharmacological studies and aiding in the development of more effective treatments for bipolar disorder (Fountoulakis et al., 2024).

      • Quantification of LurasiDonein Clinical Samples: Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying lurasiDonein dried blood spot samples was reported. This method facilitates easier and less invasive monitoring of lurasiDonelevels in patients, crucial for effective pharmacological research and ensuring therapeutic efficacy in treatment regimes (Rajadhyaksha and Londhe, 2023).

      • Novel Methodologies in Clinical Trials: Research introduced a novel method for deriving adverse event prevalence in randomized controlled trials, which could potentially improve the understanding of the benefit-risk ratio of drugs including lurasidone. This approach is particularly relevant for drug labels and regulatory submissions, ensuring safer and more effective clinical outcomes (Piacentino et al., 2024).

      • Pharmacological Properties of Lurasidone: A study investigated how lurasiDoneblocks the voltage-gated potassium channels of coronary arterial smooth muscle cells, offering insights into its broader pharmacological impacts. This research is vital for assessing potential cardiovascular side effects and optimizing dosing strategies to mitigate risks in patients treated with lurasiDone(Zhuang et al., 2023).

    Legal Information

    CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
    Latuda is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.
    Snap-N-Shoot is a registered trademark of Cerilliant Corporation
    Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

    Safety Information

    signalword

    Danger

    hcodes

    H225,H301 + H311 + H331,H370

    pcodes

    P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311

    Hazard Classifications

    Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

    target_organs

    Eyes

    wgk_germany

    WGK 1